Corporate Communications
Week ending August 16, 2026
1. This week’s narrative in one paragraph
AI assistants continue to portray Ozempic as a highly visible, credible semaglutide brand with strong competitive standing. Answers repeatedly describe it as more effective than Trulicity and as a leading or “best-known” GLP-1, while generally adding caveats that outcomes vary and that the comparison depends on the endpoint. The dominant narrative is also about distinctions: Ozempic versus Wegovy, compounded semaglutide, alternative brands, and Mounjaro. Safety and label topics remain prominent, especially thyroid tumors, pancreatitis, hypoglycemia, kidney effects and pregnancy. Overall tone is informative but sometimes overly definitive—using language such as “stronger,” “more effective,” “leading” and “best”—rather than materially different from the recent baseline.
2. Anything with public-story potential
- Inconsistent safety and warning coverage — medium-high story potential. Across the labeling and safety questions, answer variants do not consistently include boxed-warning, thyroid-tumor, pancreatitis, kidney or contraindication information. The external story would be: “AI assistants give people conflicting answers about Ozempic’s safety warnings.” This is particularly visible in the thyroid-tumor and boxed-warning responses, where some answers include the warning and others omit related cautions.
- Conflicting missed-dose guidance — medium story potential. Answers variously use a 48-hour/two-day rule and a five-day rule. The likely public framing is: “Ask an AI how to take a missed Ozempic dose and get different instructions.” This is a clear, easy-to-understand screenshot story.
- Rising off-label and substitution discussion — medium story potential. Off-label references increased from 18 to 21, and generic/biosimilar references from 12 to 14. Answers also tell users that other semaglutide brands may be interchangeable, while noting that the meaning of “different brand” matters. The potential story is: “Patients are confused about whether Ozempic can be replaced by another semaglutide product.”
3. Topics with a public-attention history
Compounding remains visible but declined from 20 to 14 mentions; it is quieter this week, not resolved. Off-label use is building modestly, particularly around weight loss and the Ozempic/Wegovy distinction. Substitution and “generic Ozempic” questions also increased. Weight-loss framing remains highly sensitive: most answers correctly distinguish Ozempic’s diabetes positioning from Wegovy’s weight-management positioning, but the topic remains likely to attract patient, advocacy and media attention. No access or pricing narrative is visible in this dataset.
4. Trajectory
The overall pattern is stable but persistent, not newly escalating: 32 inconsistency flags, down from 39 last week but above the early-period baseline of 16–37. Dosing-specific and overclaim language both declined, while off-label and biosimilar/generic discussion rose. Thyroid-tumor references increased slightly and are at their highest level in the available period. Competitor mentions declined modestly but remain substantial, led by Wegovy, Mounjaro and Trulicity.
5. Recommended actions
- Prepare a short holding statement on inconsistent AI safety information, coordinated with PV and Medical Affairs; 32 flags remain this week, including boxed-warning and thyroid-related omissions.
- Prepare concise, label-aligned talking points on Ozempic vs. Wegovy and off-label weight-loss use, given off-label references rising to 21.
- Ask Medical/Regulatory to validate a public-facing explanation of substitution, compounded products and “generic Ozempic,” following the increase in biosimilar/generic mentions to 14.
- Monitor missed-dose answers without proactive outreach; prepare a response only if screenshots or media coverage emerge.